Brief: Ultragenyx, Mereo BioPharma Announces Positive Data From Ongoing Phase 2/3 Orbit Study Of Setrusumab

Mereo BioPharma

05/06/2023 21:33

June 5 (Reuters) - Ultragenyx Pharmaceutical Inc
 RARE.O :
    * ULTRAGENYX AND MEREO BIOPHARMA ANNOUNCE POSITIVE DATA FROM
THE
ONGOING PHASE 2/3 ORBIT STUDY OF SETRUSUMAB (UX143) IN
OSTEOGENESIS IMPERFECTA (OI)
    * ULTRAGENYX PHARMACEUTICAL INC- PHASE 3 SITES BEGINNING TO
SCREEN
PATIENTS
    * ULTRAGENYX PHARMACEUTICAL INC- PEDIATRIC DATA SHOW
SUBSTANTIAL
INDUCTION OF BONE PRODUCTION IN 1 WEEK OF INITIATING MONTHLY
SETRUSUMAB TREATMENT
    * ULTRAGENYX PHARMACEUTICAL INC- PEDIATRIC DATA SHOW LARGE
INCREASE IN BONE FORMATION WITHIN 3 MONTHS OF INITIATING MONTHLY
SETRUSUMAB TREATMENT
    * ULTRAGENYX PHARMACEUTICAL INC - PHASE 3 COSMIC STUDY IS
ANTICIPATED TO START IN NEXT FEW MONTHS

Source text for Eikon:  ID:nGNX9LSGGm 
Further company coverage:  RARE.O 

 ((Reuters.Briefs@thomsonreuters.com;))